TY - JOUR
T1 - Recommendations for development of acute seizure action plans (ASAPs) from an expert panel
AU - Penovich, Patricia
AU - Glauser, Tracy
AU - Becker, Danielle
AU - Patel, Anup D.
AU - Sirven, Joseph
AU - Long, Lucretia
AU - Stern, John
AU - Dixon-Salazar, Tracy
AU - Carrazana, Enrique
AU - Rabinowicz, Adrian L.
N1 - Funding Information:
Dr. Penovich has served on speakers’ bureaus for GW Pharmaceuticals; Neurelis, Inc.; SK Life Science; and UCB, and is an advisor to Engage Therapeutics; LVIS Corporation; Neurelis, Inc.; and SK Life Science. Dr. Glauser is a consultant for Clarigent Health; Eisai Inc.; Neurelis, Inc.; Supernus Pharmaceuticals, Inc; and UCB. He receives research support from the National Institutes of Health. Dr. Becker is a speaker for Neurelis, Inc; SK Life Science; Supernus, Inc; and Neuropace, Inc, and is an advisor for Neurelis, Inc; SK Life Science; and Supernus, Inc. Dr. Patel receives research support from the National Institutes of Health and Pediatric Epilepsy Research Foundation; receives institutional research support from Stoke; receives compensation for being a member of the Greenwich Biosciences Education Content Workgroup; is an advisor for Neurelis, Inc; and receives compensation for webinar development from Medscape and Neurology Live. Dr. Sirven is an advisor for Neurelis, Inc. Ms. Long is a consultant for Neurelis, Inc.; SK Life Science; and Supernus Pharmaceuticals, and is a speaker for LivaNova. Dr. Stern is a consultant for Eisai; Neurelis, Inc.; SK Life Science; and UCB. Dr. Dixon-Salazar is a consultant for the LGS Foundation, the Chan Zuckerberg Initiative and Neurelis, Inc. Dr. Carrazana is an employee of and has received stock and stock options from Neurelis, Inc. Dr. Carrazana has received compensation for serving on the boards of directors of Marinus and Hawaii-Biotech. Dr. Rabinowicz is an employee of and has received stock options from Neurelis, Inc.
Funding Information:
The concept for this paper originated at a meeting of the Neurosciences Council that was convened in February 2020 with financial support from Neurelis. During its closed-door meeting, the Council discussed current ASAPs and opportunities for improvement. The Council resolved to produce a paper presenting the agreed upon expert opinion recommendations on ASAP development, use, content, and format.
Funding Information:
Medical writing support was provided at the direction of the authors by Laura J. Herold, MA, of The Curry Rockefeller Group, LLC (Tarrytown, NY), which also provided additional editorial assistance including formatting and proofreading, and was funded by Neurelis, Inc (San Diego, CA). Development of this manuscript was supported by Neurelis, Inc.
Publisher Copyright:
© 2021 The Author(s)
PY - 2021/10
Y1 - 2021/10
N2 - Purpose of review: Disease-related treatment action plans for acute exacerbations providing information that may be helpful for self-management for patients and caregivers are commonly used for chronic conditions such as asthma and diabetes. However, among patients with epilepsy, a review of the literature suggested that the majority did not have an action plan in place for acute seizure treatment. Recent findings: Currently, there is a lack of unified guidance on seizure action plans (SAPs) in the literature. In the authors’ opinion, available formats have limitations for practical use and may not be easily customizable to individual patients, and they are not often designed to provide simple-to-follow steps for rapid immediate steps to determine and initiate appropriate treatment of seizure emergencies. Our group reviewed current examples of SAPs and provided guidance on the development of acute seizure action plans (ASAPs) designed to facilitate rapid, appropriate acute care in the community and to be as useful as possible for a wide range of care partners, including those with limited experience. This paper provides agreed upon expert opinion recommendations and considerations for goals, development process, types of content, and format for an ASAP.
AB - Purpose of review: Disease-related treatment action plans for acute exacerbations providing information that may be helpful for self-management for patients and caregivers are commonly used for chronic conditions such as asthma and diabetes. However, among patients with epilepsy, a review of the literature suggested that the majority did not have an action plan in place for acute seizure treatment. Recent findings: Currently, there is a lack of unified guidance on seizure action plans (SAPs) in the literature. In the authors’ opinion, available formats have limitations for practical use and may not be easily customizable to individual patients, and they are not often designed to provide simple-to-follow steps for rapid immediate steps to determine and initiate appropriate treatment of seizure emergencies. Our group reviewed current examples of SAPs and provided guidance on the development of acute seizure action plans (ASAPs) designed to facilitate rapid, appropriate acute care in the community and to be as useful as possible for a wide range of care partners, including those with limited experience. This paper provides agreed upon expert opinion recommendations and considerations for goals, development process, types of content, and format for an ASAP.
KW - Rescue therapy
KW - Seizure action plan
KW - Seizure clusters
KW - Seizure emergency
KW - Status epilepticus
UR - http://www.scopus.com/inward/record.url?scp=85114171907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114171907&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2021.108264
DO - 10.1016/j.yebeh.2021.108264
M3 - Review article
C2 - 34482230
AN - SCOPUS:85114171907
SN - 1525-5050
VL - 123
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
M1 - 108264
ER -